At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 104 enrolled
Drug / intervention
ABBV-903 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 First in Human, Single and Multiple Ascending Dose and Food Effect and Drug-Drug Interaction in Healthy Subjects to Evaluate the Safety, Tolerability and Assessment of Pharmacokinetics of ABBV-903
In Brief
A Phase 1 clinical trial evaluating ABBV-903, Placebo for ABBV-903, and 1 other intervention for Healthy Volunteer. Completed, enrolled 104 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate adverse events and tolerability of single and multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy adult volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedJan 2023
Primary CompletionOct 2023
TodayJul 2026
First PostedJan 20, 2023
Enrollment StartJan 3, 2023
Primary CompletionOct 23, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.4 years ago
Interventions
ABBV-903drug
Capsule; oral
Placebo for ABBV-903drug
Capsule; oral
Itraconazoledrug
Capsule; oral